Scientists Identify Gene Vital to Early Embryonic Cells Forming a Normal Heart and Skull
In a study posted online June 15, 2009 by the Proceedings of the National Academy of Sciences, a research team at Cincinnati Childrens reports that too little of the gene/protein SHP2 interferes with the normal developmental activity of what are called neural crest cells. These cells, which occur very early in embryonic development, migrate to specific regions of the embryo. While doing so, the cells are supposed to differentiate and give rise to certain nerve tissues, craniofacial bones or smooth muscle tissue of the heart.
Our findings show that a deficiency of SHP2 in neural crest cells results in a failure of cell differentiation at diverse sites in the developing embryo, said Jeffrey Robbins, PhD, co-director of the Heart Institute at Cincinnati Childrens and senior investigator of the study. This leads to anatomical and functional deficits so severe that it precludes viability of the developing fetus.
SHP2 is a tyrosine phosphatase an enzyme that helps trigger a cascade of biochemical reactions in cells as they specify to form certain tissues.
Although the study was conducted using mouse embryos, the findings are significant in efforts to understand congenital malformations of the heart and craniofacial region in people. Especially relevant, the researchers said, is the insight gained into early molecular events during embryonic development that might help explain such birth defects.
Robbins, professor of pediatrics at the
The study was supported by grants from the National Institutes of Health. Other researchers include first author, Tomoki Nakamura, along with James Gulick, and Melissa Colbert, all of the division of molecular cardiovascular biology at Cincinnati Childrens.
Tags
Related Stories
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
At least two weather patterns increase headaches, UC study suggests
June 4, 2026
University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.
UC researcher secures $3.3M grant to study microplastics’ impact on heart
June 2, 2026
The National Institute of Environmental Health Sciences awarded a $3.3M grant to University of Cincinnati researcher Hong‑Sheng Wang, PhD, to study how microplastics and nanoplastics affect cardiovascular health.